Fresh out of stealth, Switchpoint Bio raises €4.75 million to decode disease and drug response through blood tests
Switchpoint Bio, a Helsinki- and Cambridge, Massachusetts-based TechBio startup, has raised €4.75 million ($5.3 million) in pre-Seed financing to advance a blood-based epigenomic platform that gives drug developers a scalable view of how disease and treatment change human biology. The round includes
<p>Switchpoint Bio, a Helsinki- and Cambridge, Massachusetts-based TechBio startup, has raised €4.75 million ($5.3 million) in pre-Seed financing to advance a blood-based epigenomic platform that gives drug developers a scalable view of how disease and treatment change human biology. The round includes</p>